Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Honorary Associate Professor
- Department of Targeted Intervention
- Div of Surgery & Interventional Sci
- Faculty of Medical Sciences
I graduated from the University of Cambridge in 2000, and trained in surgery in the East of Scotland. In 2005, I commenced a 3-year full-time PhD in prostate cancer genetics at Newcastle University funded by a prestigious Medical Research Council Clinical Research Training Fellowship. I moved to the West of Scotland for urology training, focussing on complex cancer surgery, and obtained urology specialist registration in 2014. In parallel, as a Clinical Lecturer at the University of Glasgow, I continued post-doctoral research at the Cancer Research UK (CR-UK) Beatson Institute. I was the first urologist in Scotland to be awarded a highly-competitive Royal College of Surgeons of England/CR-UK Clinician Scientist Fellowship in Surgery to support my research into prostate cancer. I undertook a clinical and research fellowship in robotic "keyhole" prostate cancer surgery at the Karolinska Institutet and University Hospital, Stockholm, Sweden. On my return to Glasgow in 2015, I was appointed as a Consultant Urologist specialising in laparoscopic "keyhole" kidney cancer surgery. The same year, I was recruited to University College London NHS Foundation Trust Trust, Barts Health NHS Trust, and Queen Mary University of London. In 2020, I was appointed as an honorary Associate Professor at University College London.


My laboratory-based research programme explores alternative pre-mRNA splicing (AS), a ubiquitous mechanism of gene regulation, in prostate cancer (PCa). During AS, coding (exons) and non-coding (introns) regions of a gene are shuffled to create protein isoforms with different functions. AS leads to diversity between patients and within a single patient's tumour, which confounds molecular classification and treatments. My clinical research programme explores how minimally-toxic adjunctive drug treatments may reduce PCa progression for men on active surveillance. We are also looking at ways to reduce the toxicity burden of chemotherapy and improve quality of life for patients with metastatic testicular cancer.
13-NOV-2020 | Honorary Associate Professor | Division of Surgery and Interventional Sciences | UCL, United Kingdom |
01-OCT-2015 | Honorary Consultant Urological Surgeon | Urology | Barts Health NHS Trust, United Kingdom |
01-OCT-2015 | Group Leader | Barts Cancer Institute | QMUL, United Kingdom |
01-OCT-2015 | Honorary Consultant Urological Surgeon | Urology | UCLH, United Kingdom |